CHAPTER-6

REFERENCES



6. REFERENCES

[1] Jorgensen, W. The many roles of computation in drug discovery. *Science*, **2004**, 303, 1813-1818.

[2] Kapetanovic, I. Computer aided drug discovery and development (CADDD): *In silico*-chemico-biological approach. *Chem Biol. Interact.*, **2008**, 171, 165-176.

[3] Tang, Y.; Zhu, W.; Chen, K.; Jiang, H. New technologies in computer-aided drug design: Toward target identification and new chemical entity discovery. *Drug Disc. Today: Techno.*, **2006**, 3, 307-313.

[4] Machin, P. Designing drugs-where next? In: *EuroQSAR2002: Designing Drugs and Crop Protectants: processes, problems and solutions;* Ford, M.; Livingstone, D.; Dearden, J.; Van de Waterbeemd, H. Eds.;.Blackwell Publishing: Oxford, UK., 2003, pp. 1-4.

[5] Ooms, F. Molecular modeling and computer aided drug design. Examples of their applications in medicinal chemistry. *Curr. Med. Chem.*, **2000**, 7, 141-158.

[6] Cramer III, R. D.; Patterson, D. E.; Bunce, J. D. Comparative Molecular Field Analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. *J. Am Chem Soc.*, **1988**, 110, 5959-5967.

[7] Klebe, G.; Abraham, U.; Mietzner, T. Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. *J. Med. Chem*, **1994**, 37, 4130-4146.

[8] Cho, S.; Garsia, M. *et al.* Structure-Based alignment and comparative molecular field analysis of Acetylcholinesterase inhibitors. *J. Med. Chem*, **1996**, 39, 5064-5071.

[9] Vedani, A.; Dobler, M. Multi-dimensional QSAR in drug research. Predicting binding affinities, toxicity and pharmacokinetic parameters. *Progress in Drug Research*, **2002**, 55, 105-135.

[10] Vedani, A.; Dobler, M. 5D-QSAR: The key for simulating induced fit? *J. Med. Chem*, **2002**, 45, 2139-2149.

[11] Cramer III, R.; DePriest, S.; Patterson, D.; Hecht, P. The developing practice of Comparative Molecular Field Analysis. In: *3D QSAR in drug design: Theory, Methods and Applications*, Kubinyi, H., Ed.; ESCOM, Leiden, **1993**; pp. 443-485.

[12] Holtje, H.; Sippl, W. Rognan, D. Folkers, G. *Molecular modeling: basic principles and applications*, 2nd ed.; Weinheim, Wiley-VCH Verlag Gmbh & Co. KGnA: Germany, **2003**; pp. 228.

[13] Klebe, G.; Abraham, U. On the prediction of binding properties of drug molecules by comparative molecular field analysis. *J. Med. Chem*, **1993**, 36, 70-80.

[14] Wold, S., Johansson, E., Cocchi, M. Partial Least-Squares Projections to latent structures. In: *3D QSAR in drug design: Theory, Methods and Applications*, Kubinyi, H. Ed.; ESCOM, Leiden, **1993**; pp. 523-550.

[15] Wold, S.; Ruhe, A.; Wold, H.; Dunn, W III. The collinearity in linear regression. The partial least squares (PLS) approach to generalized inverses. SIAM *J. Sci. Stat. Comput.*, **1984**, 5, 735-743.

[16] Clark, M.; Cramer, R. The probability of chance correlation using partial least squares (PLS). *Quant. Struct-Act. Relat.*, **1993**, 12, 137-145.

[17] Clark, R.; Sprous, D.; Leonard, J. Validating models based on large data sets. In: *Rational approaches to drug design*; Holtje, H-D, Sippl, W., Eds.; Prous Science: Barcelona, **2001**; pp. 475-485.

[18] Kubinyi, H., Abraham, U. Practical problems in PLS analyses. In *: 3D QSAR in drug design: Theory, Methods and Applications*, Kubinyi H, Ed.; ESCOM, Leiden, **1993**; pp. 717-728.

[19] Baroni, M., Costantino, G., Cruciani, G., Riganelli, D., Valigi, R., Clementi, S. Generating optimal linear PLS estimations (GOLPE): An advanced chemometric tool for handling 3D-QSAR problems. *Quant. Struct-Act. Relat.*, **1993**, 12, 9-20.

[20] Pastor, M.; Cruciani, G.; Clementi, S. Smart region definition: a new way to improve the predictive ability and interpretability of three-dimensional quantitative structure-activity relationships. *J. Med. Chem.*, **1997**, 40, 1455-1464.

[21] Böhm, M.; Sturzebecher, J.; Klebe, G. Three-dimensional quantitative structure-activity relationship analyses using comparative molecular field analysis and comparative molecular similarity indices analysis to elucidate selectivity differences of inhibitors binding to trypsin, thrombin, and factor Xa. *J. Med. Chem.*, **1999**, 42, 458-477.

[22] Klebe, G.; Abraham, U. Comparative molecular similarity index analysis (CoMSIA) to study hydrogen-bonding properties and to score combinatorial libraries. *J. Comput. Aided Mol. Des.*, **1999**, 13, 1-10.

[23] Thibaut, U.; Folkers, G.; Klebe, G.; Kubinyi, H.; Merz, A.; Rognan, D. Recommendations for CoMFA studies and 3D QSAR publications. In: *3D QSAR in drug design: Theory, Methods and Applications*, Kubinyi, H., Ed.; ESCOM: Leiden, **1993**; pp. 711-716.

[24] Doweyko, A, M. 3D-QSAR illusions. *J. Comput. Aided Mol.* Des., **2004**, 18, 587-596.

[25] Golbraikh, A., Shen, M, Xiao, Z., Xiao, Y.D., Lee, K.H., Tropsha, A. Rational selection of training and test sets for the development of validated QSAR models. *J. Comput. Aided Mol.* Des., **2003**, 17, 241-253.

[26] Golbraikh, A., Tropsha, A. Beware of q2! *J. Mol. Graph. Model.*, **2002**, 20, 269-276.

[27] Kubinyi, H. Validation and predictivity of QSAR models. 15th Euro-QSAR Symposium, 2004; http://www.kubinyi.de/istanbul 2004-lecture.pdf

[28] Kubinyi, H.; Hamprecht, F.A.; Mietzner, T. Three-dimensional quantitative similarity-activity relationships (3D QSAR) from SEAL similarity matrices. *J. Med. Chem.*, **1998**, 41, 2533-2564.

[29] van Drie, J. Pharmacophore discovery-lessons learned. *Curr. Pharm. Des.*, **2003**, 9, 1649-1664.

[30] Oprea, T.; Garcia, A. Three-dimensional quantitative structure-activity relationships of steroid aromatase inhibitors. *J. Comput. Aided Mol. Des.*, **1996**, 10, 186-200.

[31] Hawkins, D.; Basak, S.; Mills, D. Assessing model fit by cross-validation. *J. Chem Inf. Comput.* Sci., **2003**, 43, 579-586.

[32] Clark, R.; Fox, P. Statistical variation in progressive scrambling. *J. Comput. Aided Mol. Des.*, **2004**, 17, 1-14.

[33] Wermuth, C.; Ganellin, E; Lindberg, P.; Mitscher, L. Glossary of terms used in Medicinal Chemistry (IUPAC Recommendations 1998). *Pure and Appl. Chem*, **1998**, 70, 1129-1143.

[34] Patel, Y.; Gillet, V.; Bravi, G.; Leach, A. A comparison of the pharmacophore identification programs: Catalyst, DISCO and GASP. *J. Comput. Aided Mol. Des.*, **2002**, 16, 653-681.

[35] Ghosh, A.; Crippen, G.; Revankar, G.; McKernan, P.; Smee, D.; Robins, R. Analysis of the *in vitro* antiviral activity of certain ribonucleosides against parainfluenza virus using a normal computer-aided receptor modeling procedure. *J. Med. Chem*, **1989**, 32, 746-756.

[36] Leach, A. *Molecular modelling: principles and applications*, 2nd ed.; Essex,: Pearson Education Ltd; UK, **2001**; pp. 744.

[37] Perola, E.; Charifson, P. Conformational analysis of drug-like molecules bound to proteins: an extensive study of ligand re-organization upon binding. *J. Med. Chem*, **2004**, 47, 2499-2510.

[38] Dixon, S.; Smondyrev, A.; Knoll, E.; Rao, S.; Shaw, D.; Friesner, R. PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results. *J. Comput. Aided Mol. Des.*, **2006**, 20, 647-667.

[39] Martin, Y. DISCO: *What we did right and what we missed.* In: Guner, O.F. Pharmacophore perception, development, and use in drug design. International University Line, La Jolla, CA, **2000**; pp. 49-68.

[40] Martin, Y.; Bures, M.; Danaher, E.; DeLazzer, J.; Lico, I.; Pavlik, P. A fast new approach to pharmacophore mapping and its application of dopaminergic and benzodiazepine agonist. *J. Comput. Aided Mol. Des.*, **1993**, 7, 83-102.

[41] Barnum, D.; Greene, J. Smellie, A.; Sprague P. Identification of common functional configurations among molecules. *J. Chem Inf. Comput. Sci.*, **1996**, 36, 563-571.

[42] Clement, O.; Trope-Mehl, A. HipHop: Pharmacophores based on multiple common-feature alignments. In: Guner, O. F. *Pharmacophore Perception, Development, and Use in Drug Design*, International University Line, La Jolla, CA, 2000; pp. 69-83.

[43] Jones, G.; Willett, P.; Glen, R. A genetic algorithm for flexible molecular overlay and pharmacophore elucidation. *J. Comput. Aided Mol. Des.*, **1995**, 9, 532-549.

[44] Bordoli, L.; Kiefer, F.; Arnold, K.; Benkert, P.; Battey, J.; Schwede, T. Protein structure homology modeling using SWISS-MODEL workspace. *Nature Protocols*, 2009, 4, 1-13.

[45] Anderson, A. The process of Structure-based Drug Design. *Chem Biol.*, 2003, 10, 787-798.

[46] Berman, H.; Battistuz, T.; Bhat, T.; Bluhm, W.; Bourne, P.; Burkhardt, K.; Feng, Z.; Gilliland, G.; Iype, L.; Jain, S.; Fagan, P.; Marvin, J.; Padilla, D.; Ravichandran, V.; Schneider, B.; Thanki, N.; Weissig, H.; Westbrook, J. D.; Zardecki, C. The protein data bank. *Acta Crystallogr. D. Biol.. Crystallogr.*, 2002, 58, 899-907.

[47] Bairoch, A.; Apweiler, R. Wu, C.; Barker, W.; Boeckmann, B.; Ferro, S.; Gasteiger, E.; Huang, H.; Lopez, R.; Magrane, M.; Martin, M.; Natale, D.; O'Donovan, C.; Redaschi, N.; Yeh, L. The Universal Protein Resource (UniProt). *Nucleic acids Res.*, 2005, 33, D154-159.

[48] Bonneau, R.; Baker, D. *Ab initio* protein structure prediction: Progress and prospects. *Annu. Rev Biophys. Biomol Struct.*, 2001, 30, 173-189.

[49] Chivian, D.; Robertson, T.; Bonneau, R.; Baker, D. *Ab initio* methods. *Biochem Anal.*, 2003, 44, 547-557.

[50] Jones, D.; Miller, R.; Thornton, J. Successful protein fold recognition by optimal sequence threading validated by rigorous blind testing, *Proteins*, **1995**, 23, 387-397.

[51] Miller, R.; Jones, D.; Thornton, J. Protein fold recognition by sequence threading: tools and assessment techniques. *FASEB. J.*, **1996**, 10, 171-178.

[52] Blundell, T.; Sibanda, B.; Sternberg, M.; Thornton, J. Knowledge-based prediction of protein structures and the design of novel molecules. *Nature*, **1987**, 326, 347-352.

[53] Johnson, M.; Srinivasan, N.; Sowdhamini, R.; Blundell, T. Knowledge-based protein modeling. *Crit. Rev Biochem Mol. Biol.*, **1994**, 29, 1-68.

[54] Fiser, A. Protein structure modeling in the proteomics era. *Expert Rev Proteomics*, 2004, 1, 97-110.

[55] Altschul, S.; Madden, T.; Schaffer, A.; Zhang, J.; Zhang, Z.; Miller, W.; Lipman, D. Gapped BLAST and PSI-BLAST: A new generation of protein database search programs. *Nucleic Acids Res.*, **1997**, 25, 3389-3402.

[56] Chenna, R.; Sugawara, H.; Koike, T. Lopez, R.; Gibson, T.; Higgins, D.; Thompson, J. Multiple sequence alignment with the Clustal series of programs. *Nucleic Acids Res.*, **2003**, 31, 3497-3500.

[57] Marti-Renom, M.; Madhusudhan, M.; Sali, A. Alignment of protein sequences by their profiles. *Protein Sci.*, **2004**, 13, 1071-1087.

[58] Laskowski, R.; MacArthur, M.; Moss, D.; Thornton, J. PROCHECK: A program to check the stereochemical quality of protein structures. *J. Appl. Cryst.*, **1993**, 26, 283-291.

[59] Hooft, R.; Vriend, G.; Sander, C.; Abola, E. Errors in protein structures. *Nature*, **1996**, 381, 272-272.

[60] Arnold, K.; Bordoli, L.; Kopp, J.; Schwede, T. The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. *Bioinform*, **2006**, 22, 195–201.

[61] Sali, A.; Blundell, T. Comparative protein modelling by satisfaction of spatial restraints. *J. Mol. Biol.*, **1993**, 234, 779-815.

[62] Jacobson, M.; Pincus, D.; Rapp, C.; Day, T.; Honig, B.; Shaw, D.; Friesner, R. A hierarchical approach to all-atom protein loop prediction. *Proteins*, **2004**, 55, 351–367.

[63] Karlsson, M.; Contreras, J. A.; Hellman, U. Tornqvist, H.; Holm, C. cDNA cloning, tissue distribution, and identification of the catalytic triad of monoglyceride lipase. Evolutionary relationship to esterases, lysophospholipases, and haloperoxidases. *J. Biol. Chem.*, **1997**, 272, 27218-27223.

[64] Radlinska, M.; Kondrzycka-Dada, A. Piekarowicz, A.; Bujnicki, J. Identification of amino acids important for target recognition by the DNA:m5C methyltransferase M.NgoPII by alanine-scanning mutagenesis of residues at the protein-DNA interface. *Proteins*, **2005**, 58, 263-270.

[65] McAllister, S.; Rizvi, G.; Anavi-Goffer, S.; Hurst, D.; Barnett-Norris, J.; Lynch, D.; Reggio, P.; Abood, M. An aromatic microdomain at the cannabinoid CB(1) receptor constitutes an agonist/inverse agonist binding region. *J. Med. Chem.*, **2003**, 46, 5139-5152.

[66] Bissantz, C. Conformational changes of G protein-coupled receptors during their activation by agonist binding. *J. Recept. Signal Transduct. Res.*, **2003**, 23, 123-153.

[67] Evers, A.; Klabunde, T. Structure-based drug discovery using GPCR homology modeling: successful virtual screening for antagonists of the alpha1A andrenergic receptor. *J. Med. Chem*, **2005**, 48, 1088-1097.

[68] Alder, B.; Wainwright, T. Studies in molecular dynamics. I. General method. *J. Chem Phys.*, **1959**, 31, 459-466.

[69] Alder, B.; Wainwright, T. Studies in molecular dynamics. II. Behavior of a small number of elastic spheres. *J. Chem Phys.*, **1960**, 33, 1439–1451.

[70] Rahman, A. Correlations in the motion of atoms in liquid argon. *Phys. Rev*, **1964**, 136, A405.

[71] Rahman, A.; Stillinger, F. Propagation of sound in water. A molecular dynamics study. *Phys. Rev*, **1974**, 10, 368-378.

[72] McCammon, J., Gelin, B.; Karplus, M.; Wolynes, P. The hinge-bending mode in lysozyme. *Nature*, **1976**, 262, 325–326.

[73] McCammon, J.; Gelin, B.; Karplus, M. Dynamics of folded proteins. *Nature*, **1977**, 267, 585–590.

[74] Saxena, A.; Wong, D.; Diraviyam, K.; Sept, D. The Basic Concepts of Molecular Modeling, *Methods Enzymol.*, **2009**, 467, 307-330.

[75] Major, D.; Fischer, B. Molecular recognition in purinergic receptors. 1. A comprehensive computational study of the h-P2Y1-receptor. *J. Med. Chem.*, **2004**, 47, 4391-4404.

[76] Varady, J.; Wu, X.; Fang, X. Min, J.; Hu, Z.; Levant, B.; Wang, S. Molecular modeling of the three-dimensional structure of dopamine 3(D3) subtype receptor: discovery of novel and potent D3 ligands through a hybrid pharmacophore and structure-based database searching approach. *J. Med. Chem.*, **2003**, 46, 4377-4392.

[77] Fuxreiter, M.; Magyar, C.; Juhasz, T. Szeltner, Z.; Polgár, L.; Simon, I. Flexibility of prolyl oligopeptidase: molecular dynamics and molecular framework analysis of the potential substrate pathways. *Proteins*, **2005**, 60, 504-512.

[78] Roccatano, D.; Mark, A.; Hayward, S. Investigation of the mechanism of domain closure in citrate synthase by molecular dynamics simulation. *J. Mol. Biol.*, **2001**, 310, 1039-1053.

[79] Sanjeev, B.; Vishveshwara, S. Dynamics of the native and ligand-based structures of eosinophil cationic protein: network of hydrogen bonds at the catalytic site. *J. Biomol. Struct. Dyn.*, **2005**, 22, 657-672.

[80] Kirkpatrick, S.; Gelatt, C.; Vecchi, M. Optimization by simulated annealing. *Science*, **1983**, 220, 671-680.

[81] McGann, M.; Almond, H.; Nicholls, A. Gaussian docking functions. *Biopolymers*, **2003**, 68, 76-90.

[82] Rarey, M.; Kramer, B.; Lengauer, T. A fast flexible docking method using an incremental construction algorithm. *J. Mol. Biol*, **1996**, 261, 470-489.

[83] Jones, G.; Willett, P.; Glen, R.; Leach, A,; Taylor, R. Development and validation of a genetic algorithm for flexible docking. *J. Mol. Biol.*, **1997**, 267, 727-748.

[84] Baxter, C.; Murray, C.; Clark, D.; Westhead, D.; Eldridge, M. Flexible docking using Tabu search and an empirical estimate of binding affinity. *Proteins*, **1998**, 33, 367-382.

[85] Hart, T.; Read, R. A multiple-start Monte Carlo docking method. *Proteins*, **1992**, 13, 206-222.

[86] Davis, A.; Teague, S. Hydrogen bonding, hydrophobic interactions, and failure of the rigid receptor hypothesis. *Angew Chem Int. Ed.*, **1999**, 38, 737-749.

[87] Fritz, T.; Tondi, D.; Finer-Moore, J.; Costi, M.; Stroud, R. Predicting and harnessing protein flexibility in the design of species-specific inhibitors of thymidylate synthase. *Chem Biol.*, **2001**, 10, 981-995.

[88] Claussen, H.; Buning, C.; Rarey, M.; Lengauer, T. FlexE: Efficient molecular docking considering protein structure variations. *J. Mol. Biol.*, **2001**, 308, 377-395.

[89] Schenecke, V.; Kuhn, L. Virtual screening with solvation and ligand-induced complementarity. *Perspect. Drug. Discov. Des.*, **2000**, 20, 171-190.

[90] Lyne, P. Structure-based virtual screening: an overview. *Drug Discov. Today*, **2002**, 7, 1047-1055.

[91] Kollman, P. Free energy calculations: Applications to chemical and biochemical phenomena. *Chem Rev*, **1993**, 93, 2395-2417.

[92] Wang, R.; Lu, Y.; Wang, S. Comparative evaluation of 11 scoring functions for molecular docking. *J. Med. Chem.*, **2003**, 46, 2287-2303.

[93] Bissantz, C.; Folkers, G.; Rognam, D. Protein-based virtual screening of chemical databases. I. Evaluation of different docking/scoring combinations. *J. Med. Chem*, **2000**, 43, 4759-4767.

[94] Charifson, P.; Corkery, J.; Murko, M.; Walters, W. Consensus scoring: A method for obtaining improved hit rates from docking databases of three-dimensional structures into proteins. *J. Med. Chem.*, **1999**, 42, 5100-5109.

[95] Sippl, W. Receptor-based 3D QSAR analysis of estrogen receptor ligands--merging the accuracy of receptor-based alignments with the computational efficiency of ligand-based methods. *J. Comput. Aided Mol. Des.*, **2000**, 14, 559-572.

[96] Söderholm, A.; Lehtovuori, P.; Nyronen, T. Three-dimensional structure-activity relationships of nonsteroidal ligands in complex with androgen receptor ligand-binding domain. *J. Med. Chem.*, **2005**, 48, 917-925.

[97] Kunick, C.; Lauenroth, K.; Wieking, K.; Xie, X.; Schultz, C.; Gussio, R.; Zaharevitz, D.; Leost, M.; Meijer, L.; Weber, A.; Jørgensen, F. S.; Lemcke, T. Evaluation and comparison of 3D-QSAR CoMSIA models for CDK1, CDK5 and GSK-3 inhibition by paullones. *J. Med. Chem.*, **2004**, 47, 22-36.

[98] Tikhonova, I.; Baskin, II.; Palyulin, V.; Zefirov, N. CoMFA and homology-based models of the glycine binding site of N-methyl-d-aspartate receptor. *J. Med. Chem.*, 2003, 46, 1609-1616.

[99] Xu, Y.; Liu, H.; Niu, C.; Luo, C.; Luo, X.; Shen, J.; Chen, K.; Jiang, H. Molecular docking and 3D QSAR studies on 1-amino-2-phenyl-4-(piperidin-1-yl)-butanes based on the structural modelling of human CCR5 receptor. *Bioorg. Med. Chem.*, 2004, 12, 6193-6208.

[100] Kuo, C.; Assefa, H.; Kamath, S.; Brzozowski, Z.; Slawinski, J.; Saczewski, F.; Buolamwini, J.; Neamati, N. Application of CoMFA and CoMSIA 3D-QSAR and docking studies in optimization of mercaptobenzenesulfonamides as HIV-1 integrase inhibitors. *J. Med. Chem*, 2004, 47, 385–399.

[101] Jones, G.; Willett, P.; Glen, R. A genetic algorithm for flexible molecular overlay and pharmacophore elucidation. *J. Comput. Aided Mol. Des.*, 1995, 9, 532–549.

[102] Friesner, R.; Banks, J.; Murphy, R.; Halgren, T.; Klicic, J.; Mainz, D.; Repasky, M.; Knoll, E.; Shelley, M.; Perry, J.; Shaw, D.; Francis, P.; Shenkin, P. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy, *J. Med. Chem.*, 2004, 47, 1739–1749.

[103] Halgren, T.; Murphy, R.; Friesner, R. Beard, H.; Frye, L.; Pollard, W.; Banks, J. Glide: A new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening, *J. Med. Chem.*, 2004, 47, 1750–1759.

[104] Ewing, T.; Makino, S.; Skillman, A.; Kuntz, I. DOCK 4.0: Search strategies for automated molecular docking of flexible molecule databases, *J. Comput. Aided Mol. Des.*, 2001, 15, 411–428.

[105] Stahl, M.; Guba, W; Kansy, M. Integrating molecular design resources within modern drug discovery research: the Roche experience. *Drug Discov Today*, 2006, 11, 326–333.

[106] Chen, Z.; Li, H.; Zhang, Q.; Bao, X.; Yu, K. Q.; Luo, X. M.; Zhu, W. L.; Jiang, H. L. Pharmacophore-based virtual screening versus docking-based virtual screening: a benchmark comparison against eight targets. *Acta Pharmacol. Sin.*, 2009, 30, 1694–1708.

[107] Shoichet, B. Virtual screening of chemical libraries. *Nature*, 2004, 432, 862-865.

[108] Davis, A.; Teague, S.; Kleywegt, G. Application and limitations of X-ray crystallographic data in strtucture-based ligand and drug design. *Angew Chem Int. Ed.*, 2003, 42, 2718-2736.

[109] Millier, M. A. Chemical database techniques in drug discovery. *Nat. Rev Drug Discov.*, 2002, 1, 220-227.

[110] McGovern, S.; Shoichet, B. Information decay in molecular docking screens against holo, apo, and modelled conformations of enzymes. *J. Med. Chem.*, 2003, 46, 2895-2907.

[111] Becker, O.; Marantz, Y.; Shacham, S.; Inbal, B.; Heifetz, A.; Kalid, O.; Bar-Haim, S.; Warshaviak, D.; Fichman, M.; Noiman, S. G Protein-coupled receptors: *In silico* drug discovery in 3D. *Proc. Natl. Acad. Sci. USA*, 2004, 101, 11304-11309.

[112] Bissantz, C.; Bernard, P.; Hibert, M.; Rognan, D. Protein-based virtual screening of chemical databases. II. Are homology models of G-Protein Coupled Receptors suitable targets? *Proteins*, 2003, 50, 5-25.

[113] Evers, A.; Klabunde, T. Structure-based drug discovery using GPCR homology modelling: successful virtual screening for antagonists of alpha1A adrenergic receptor. *J. Med. Chem*, 2005, 48, 1088-1097.

[114] Evers, A.; Klebe, G. Ligand-supported homology modelling of G-protein-coupled receptor sites: models sufficient for successful virtual screening. *Angew. Chem. Int. Ed.*, 2004, 43, 248-251.

[115] Evers, A.; Klebe, G. Successful virtual screening for a submicromolar antagonist of the neurokinin-1 receptor based on a ligand-supported homology model. *J. Med. Chem.*, 2004, 47, 5381-5392.

[116] Shacham, S.; Marantz, Y.; Bar-Haim, S.; Kalid, O. *et al.* PREDICT modeling and in-silico screening for G-protein coupled receptors. *Proteins*, 2004, 57, 51-86.

[117] Vilar, S.; Karpiak, J.; Costanzi, S. Ligand and structure-based models for the prediction of ligand-receptor affinities and virtual screenings: Development and application to the beta(2)-adrenergic receptor. *J. Comput. Chem.*, 2010, 31, 707-720.

[118] Hoffren, A. M.; Murray, C. M.; Hoffmann, R. D. Structure-based focusing using pharmacophores derived from the active site of 17 beta hydroxysteroid dehydrogenase. *Curr. Pharm. Des.*, 2001, 7, 547-566.

[119] Reddy, A.; Pati, S.; Kumar, P.; Pradeep, H.; Sastry, N. Virtual Screening in Drug Discovery- A Computational Perspective, *Curr. Protein Pept. Sci.*, 2007, 8, 331-353.

[120] McInnes, C. Virtual screening strategies in drug discovery. *Curr. Opin. Chem. Biol.*, 2007, 11, 494–502.

[121] Lipinski, C.; Lombardo, F.; Dominy, B.; Freeney, P. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development setting. *Adv. Drug Deliv. Rev.*, 2001, 46, 3-26.

[122] Lyne, P. Structure-based virtual screening: An overview. *Drug Discov. Today*, 2002, 7, 1047-1055.

[123] Miller, M. Chemical database techniques in drug discovery. *Nat. Rev. Drug Discov.*, 2002, 1, 220-227.

[124] Walters, W.; Stahl, M.; Murcko, M. Virtual screening-an overview. *Drug Discov. Today*, 1998, 3, 160-178.

[125] Fechner, U.; Schneider G. Flux (1): A Virtual Synthesis Scheme for Fragment-Based de Novo Design, *J. Chem. Inf. Model.*, 2006, 46, 699-707.

[126] Lowrie, J.; Delisle, R.; Hobbs, D.; Diller, D. The Different Strategies for Designing GPCR and Kinase Targeted Libraries. *Comb. Chem High Throughput Screen.*, 2004, 7, 495-510.

[127] Eisen, M.; Wiley, D.; Karplus, M.; Hubbard, R. *Protein Struct. Funct. Gent.*, **1994**, 19, 199-221.

[128] Nishibata, Y.; Itai, A. Confirmation of usefulness of a structure construction program based on three-dimensional receptor structure for rational lead generation *J. Med. Chem.*, **1993**, 36, 2921-2928.

[129] Bohacek, R.; McMartin, C. Multiple Highly Diverse Structures Complementary to Enzyme Binding Sites: Results of Extensive Application of a *de Novo* Design Method Incorporating Combinatorial Growth *J. Am Chem Soc.*, 116, **1994**, 5560-5571.

[130] Law, J.; Fung, D.; Zsoldos, Z.; Simon, A.; Szabo, Z.; Csizmadia, I.; Johnosn, A. Validation of the SPROUT de novo design program, *J. Mol. Struct. (Theochem)*, 2003, 666–667, 651–657.

[131] Stahura, F.; Bajorath, J. New Methodologies for Ligand-based Virtual Screening. *Curr. Pharm Des.*, 2005, 11, 1189-1202.

[132] Willett, P. Chemical Similarity Searching. *J. Chem Inf. Comput. Sci.*, **1998**, 983-996.

[133] Schuller, A.; Suhartono, M.; Uli, F.; Yusuf, T.; Sven, B.; Ute, S.; Michael, W.; Gobel, G. The concept of template-based de novo design from drug-derived molecular fragments and its application to TAR RNA. *J. Comput. Aided Mol. Des.*, 2008, 2, 59–68.

[134] Kumar, A.; Siddiqi, M. CoMFA based de novo design of Pyrrolidine Carboxamides as Inhibitors of Enoyl Acyl Carrier Protein Reductase from Mycobacterium tuberculosis. *J Mol. Model.*, 2008, 14, 923–935.

[135] Schneider, G.; Fechner, U. Computer-based *de Novo* Design of Druglike Molecules. *Nat. Rev Drug Disco.*, 2005, 4, 649-663.

[136] Propst, C.; Perun, T. Introduction to Computer-Aided drug Design, In *Computer-Aided Drug Design Methods and Applications*; Perun, T.J.; Propst, C. L. Marcel Dekker, Inc, New York, **1989**; pp. 6-10.

[137] Shaikh, S.; Jain, T.; Sandhu, G.; Latha, N; Jayaram, B. From Drug Targets to Leads-Sketching A Physicochemical Pathway for Lead Molecule Design *In Silico*, *Curr. Pharma. Design*, 2007, 13, 3454-3470.

[138] Burger, A. The conceptual background and development of medicinal chemistry. In *Burger's Medicinal Chemistry*; 5th Ed., Vol 1, Wolff, M. E. Ed.; Wiley Interscience, New York, **1995**, pp. 3-8.

[139] Kicska, G.; Long, L.; Hörig, H.; Fairchild, C.; Tyler, P.; Furneaux, R.; Schramm, V.; Kaufman, H. Immucillin H, a powerful transition-state analog inhibitor of

purine nucleoside phosphorylase, selectively inhibits human T lymphocytes. *Proc. Natl. Acad. Sci. U S A.*, 2001, 98, 4593-4598.

[140] Muscate, A.; Kenyon, G. Approaches to the rational design of enzyme inhibitors. In *Burger's Medicinal Chemistry*, 5th Ed., Vol.1, Wolff, M. E. Ed.; Wiley Interscience, New York, 1995, pp. 733-782.

[141] Majithia, V.; Geraci, S. Rheumatoid arthritis: diagnosis and management. *Am J. Med.*, 2007, 120, 936-939.

[142] Firestein, G. Etiology and pathogenesis of rheumatoid arthrities. In *Kelley's Textbook of Rheumatology*, Ruddy, S. E. A., Ed. Saunders Company: W.B., 2001; pp. 921-966.

[143] Insel, P. Analgesic-antipyretic and anti-inflammatory agents and drugs employed in the treatment of gout. In *Goodman's & Gilman's The Pharmacological Basis of Therapeutics*, Hardmann, J. G. L., L. E.; Molinoff, P. B.; Ruddon, R. W.; Gilman, A. G., Eds. McGraw Hill: New York, 1996; pp. 617-647.

[144] Kirwan, J. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. *N. Engl. J. Med.*, 1995, 333, 142-146.

[145] Weinblatt, M.; Trentham, D.; Fraser, P.; Holdsworth, D.; Falchuk, K.; Weissman, B.; Coblyn, J. Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis. *Arthritis Rheum*, 1988, 31, 167-175.

[146] DiPiro, J. *Pharmacotherapy: A Pathophysiologic Approach*. 5th ed.; McGraw-Hill publication: New York, 2002; pp. 1623-1638.

[147] Balint, G.; Szebenyi, B., Non-pharmacological therapies in osteoarthritis. *Baillieres Clin. Rheumatol.* 1997, 11, 795-815.

[148] Oppenheim, J. Introduction to the role of cytokine in innate host defense and adaptive immunity. In *Cytokine Reference*, Oppenheim, J. J. F., M, Eds. Academic Press: New York, 2001; pp. 3-20.

[149] Feldmann, M,; Brennan, F.; Maini R. Role of cytokines in rheumatoid arthritis. *Annu. Rev. Immunol.*, 1996, 14, 397-340.

[150] Odeh, M. New insights into the pathogenesis and treatment of rheumatoid arthritis. *Clin. Immunol. Immunopathol.*, 1997, 83, 103-116.

[151] Kalden, J.; Manger, M. Biologic agents in the treatment of inflammatory rheumatic diseases. *Curr. Opin. Rheumatol.*, 1997, 9, 206-212.

[152] Haslett, C.; Boon, N. Diseases of the connective tissues, joints and bones. In *Davidson's Principles and Practice of Medicine*, Nuki, J. R., S.H.; Luqmani, R., Eds. Churchill Livingstone: New York, 1999; pp. 835-55.

[153] Feldmann, M.; Elliott, M. J.; Woody, J. N.; Maini, R. N., Anti-tumor necrosis factor-alpha therapy of rheumatoid arthritis. *Adv Immunol.*, 1997, *64*, 283-350.

[154] Feldmann, M.; Bondeson, J.; Brennan, F.; Foxwell, B.; Maini, R. The rationale for the current boom in anti-TNFalpha treatment. Is there an effective means to define therapeutic targets for drugs that provide all the benefits of anti-TNFalpha and minimise hazards? *Ann. Rheum Dis.*, **1999**, 58 Suppl 1, I27-I31.

[155] Charles, P.; Elliott, M.; Davis, D.; Potter, A.; Kalden, J.; Antoni, C.; Breedveld, F. ; Smolen, J.; Eberl, G.; deWoody, K.; Feldmann, M.; Maini, R. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. *J. Immunol.*, **1999**, 163, 1521-1528.

[156] Carswell, E.; Old, L.; Kassel, R.; Green, S.; Fiore, N.; Williamson, B., An endotoxin-induced serum factor that causes necrosis of tumors. *Proc. Natl. Acad. Sci. USA.*, **1975**, *72*, 3666-3670.

[157] Pennica, D.; Nedwin, G.; Hayflick, J.; Seeburg, P.; Derynck, R.; Palladino, M.; Kohr, W.; Aggarwal, B.; Goeddel, D. Human tumour necrosis factor: Precursor structure, expression and homology to lymphotoxin. *Nature*, **1984**, 312, *724-729*.

[158] Newton, R.; Decicco, C. Therapeutic potential and strategies for inhibiting tumor necrosis factor-alpha. *J. Med. Chem*, **1999**, 42, 2295-2314.

[159] Baugh, J.; Bucala, R., Mechanisms for modulating TNF alpha in immune and inflammatory disease. *Curr. Opin. Drug Discov. Devel.*, **2001**, 4, 635-650.

[160] Tracey, K.; Cerami, A. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. *Annu. Rev. Med.*, **1994**, 45, 491-503.

[161] Evans, T.; Moyes, D.; Carpenter, A.; Martin, R.; Loetscher, H.; Lesslauer, W.; Cohen, J. Protective effect of 55- but not 75-kD soluble tumor necrosis factor receptor-immunoglobulin G fusion proteins in an animal model of *Gram negative* sepsis. *J. Exp. Med.*, **1994**, 180, 2173-2179.

[162] Tartaglia, L.; Pennica, D.; Goeddel, D. Ligand passing: the 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor. *J. Biol. Chem*, **1993**, 268, 18542-18548.

[163] Odeh, M. Role of cytokines in rheumatoid arthritis. *Drug News Perspect.*, **1998**, 11, 331-341.

[164] Klebanoff, S.; Vadas, M.; Harlan, J.; Sparks, L.; Gamble, J.; Agosti, J.; Waltersdorph, A. Stimulation of neutrophils by tumor necrosis factor. *J. Immunol.* **1986**, 136, 4220-4225.

[165] Hotamisligil, G.; Arner, P.; Caro, J.; Atkinson, R.; Spiegelman, B. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. *J. Clin. Invest.*, **1995**, 95, 2409-2415.

[166] Taylor, P. Anti-TNFalpha therapy for rheumatoid arthritis: an update. *Intern. Med.*, 2003, 42, 15-20.

[167] Palladino, M.; Bahjat, F.; Theodorakis, E.; Moldawer, L. Anti-TNF-alpha therapies: the next generation. *Nat. Rev. Drug. Discov.* **2003**, 2, 736-746.

[168] Furst, D.; Keystone, E.; Breedveld, F.; Kalden, J.; Smolen, J.; Antoni, C.; Burmester, G.; Crofford, L.; Kavanaugh, A. Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis and other rheumatic diseases (April 2001). *Ann. Rheum. Dis.*, **2001**, 60 Suppl 3, iii2-5.

[169] Lorenz, H.; Kalden, J. Perspectives for TNF-alpha-targeting therapies. *Arthritis Res.*, **2002**, 4 Suppl 3, S17-24.

[170] Hasegawa, A.; Takasaki, W.; Greene, M.; Murali, R., Modifying TNFalpha for therapeutic use: a perspective on the TNF receptor system. *Mini Rev. Med. Chem*, **2001**, 1, 5-16.

[171] Newton, R.; Solomon, K.; Covington, M.; Decicco, C.; Haley, P.; Friedman, S.; Vaddi, K. Biology of TACE inhibition. *Ann. Rheum. Dis.*, **2001**, 60 Suppl 3, iii25-32.

[172] Stocker, W.; Grams, F.; Baumann, U.; Reinemer, P.; Gomis-Ruth, F. X.; McKay, D.; Bode, W., The metzincins--topological and sequential relations between the astacins, adamalysins, serralysins, and matrixins (collagenases) define a superfamily of zinc-peptidases. *Protein Sci.*, **1995**, 4, 823-840.

[173] Black, R.; Rauch, C.; Kozlosky, C.; Peschon, J.; Slack, J.; Wolfson, M.; Castner, B.; Stocking, K.; Reddy, P.; Srinivasan, S.; Nelson, N.; Boiani, N.; Schooley, K. A.; Gerhart, M.; Davis, R.; Fitzner, J.; Johnson, R.; Paxton, R.; March, C.; Cerretti, D. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. *Nature*, **1997**, 385, 729-733.

[174] Moss, M.; Jin, S.; Milla, M.; *et al.* Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. *Nature*, **1997**, 385, 733-736.

[175] Milla, M.; Leesnitzer, M.; Moss, M.; Clay, W.; Carter, H.; Miller, A.; Su, J.; Lambert, M.; Willard, D.; Sheeley, D.; Kost, T.; Burkhart, W.; Moyer, M.; Blackburn, R.; Pahel, G.; Mitchell, J.; Hoffman, C.; Becherer, J. Specific sequence elements are required for the expression of functional tumor necrosis factor-alpha-converting enzyme (TACE). *J. Biol. Chem*, **1999**, 274, 30563-30570.

[176] Maskos, K.; Fernandez-Catalan, C.; Huber, R.; Bourenkov, G.; Bartunik, H.; Ellestad, G.; Reddy, P.; Wolfson, M.; Rauch, C.; Castner, B.; Davis, R.; Clarke, H.; Petersen, M.; Fitzner, J.; Cerretti, D.; March, C.; Paxton, R.; Black, R.; Bode, W. Crystal structure of the catalytic domain of human tumor necrosis factor-alpha-converting enzyme. *Proc. Natl. Acad. Sci. U S A*, **1998**, 95, 3408-3412.

[177] Schlondorff, J.; Blobel, C. Metalloprotease-disintegrins: modular proteins capable of promoting cell-cell interactions and triggering signals by protein-ectodomain shedding. *J. Cell Sci.*, **1999**, 112, 3603-3617.

[178] Black, R. Tumor necrosis factor-alpha converting enzyme. *Int. J. Biochem. Cell Biol.* **2002**, 34, 1-5.

[179] Reddy, P.; Slack, J.; Davis, R.; Cerretti, D.; Kozlosky, C.; Blanton, R.; Shows, D.; Peschon, J.; Black, R. Functional analysis of the domain structure of tumor necrosis factor-alpha converting enzyme. *J. Biol. Chem*, 2000, 275, 14608-14614.

[180] Diaz-Rodriguez, E.; Montero, J.; Esparis-Ogando, A.; Yuste, L.; Pandiella, A., Extracellular signal-regulated kinase phosphorylates tumor necrosis factor alpha-converting enzyme at threonine 735: a potential role in regulated shedding. *Mol. Biol. Cell*, 2002, 13, 2031-2044.

[181] Tang, P.; Hung, M.; Klostergaard, J. Length of the linking domain of human pro-tumor necrosis factor determines the cleavage processing. *Biochemistry*, 1996, 35, 8226-8233.

[182] Perez, C.; Albert, I.; DeFay, K.; Zachariades, N.; Gooding, L.; Kriegler, M., A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact. *Cell*, 1990, 63, 251-258.

[183] Peschon, J.; Slack, J.; Reddy, P.; Stocking, K.; Sunnarborg, S.; Lee, D.; Russell, W. ; Castner, B.; Johnson, R.; Fitzner, J.; Boyce, R.; Nelson, N.; Kozlosky, C.; Wolfson, M.; Rauch, C.; Cerretti, D.; Paxton, R.; March, C.; Black, R. An essential role for ectodomain shedding in mammalian development. *Science*, 1998, 282, 1281-1284.

[184] Fan, H.; Derynck, R., Ectodomain shedding of TGF-alpha and other transmembrane proteins is induced by receptor tyrosine kinase activation and MAP kinase signaling cascades. *EMBO J*, 1999, 18, 6962-6972.

[185] Moscona, A., Neuraminidase Inhibitors for Influenza, *N. Engl. J. Med.*, 2005, 353, 1363-1373.

[186] Chand, P.; Babu, Y.; Bantia, S.; Rowland, S.; Dehghani, A.; Kotian, P.; Hutchison, T.; Ali, S.; Brouillette, W.; El-Kattan, Y.; Lin, T. Syntheses and neuraminidase inhibitory activity of multisubstituted cyclopentane amide derivatives. *J. Med. Chem.*, 2004, 47, 1919-1929.

[187] Neumann, G.; Noda, T.; Kawaoka, Y. Emergence and pandemic potential of swine-origin H1N1 influenza virus. *Nature*, 2009, 459, 931-939.

[188] Use of antiviral drugs against influenza A(H1N1). http://www.who.int/csr/disease/swineflu/frequently_asked_questions/swineflu_faq_antivirals/en/index.html

[189] Pandemic (H1N1) 2009 briefing note. http://www.who.int/csr/disease/swineflu/notes/h1n1_antiviral_resistance_20090708/en

[190] Babu, Y.; Chand, P.; Bantia, S.; Kotian, P, Dehghani A, El-Kattan, Y.; Lin, T.; Hutchison, T.; Elliott, A.; Parker, C.; Ananth, S.; Horn, L.; Laver, G.; Montgomery, J. BCX-1812 (RWJ-270201): Discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. *J. Med. Chem*, 2000, 43, 3482-3486.

[191] Matrosovich, M.; Matrosovich, T.; Gray, T.; Roberts, N.; Klenk, H. Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. *J. Virol.*, **2004**, 78, 12665-12667.

[192] Meindl, P.; Bodo, G.; Palese, P.; Schulman, J.; Tuppy, H., Inhibition of neuraminidase activity by derivatives of 2-deoxy-2,3-dehydro-N-acetylneuraminic acid. *Virology*, **1974**, 58, 457-463.

[193] Palese, P.; Compans, R. Inhibition of influenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid (FANA): Mechanism of action. *J. Gen. Virol.*, **1976**, 33, 159-163.

[194] Palese, P.; Schulman, J.; Bodo, G.; Meindl, P. Inhibition of influenza and parainfluenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid (FANA). *Virology*, **1974**, 59, 490-498.

[195] Varghese, J.; McKimm-Breschkin, J.; Caldwell, J.; Kortt, A.; Colman, P. The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor. *Proteins*, **1992**, 14, 327-332.

[196] von Itzstein, M.; Wu, W-Y.; Kok, G. *et al.*, Rational design of potent sialidase-based inhibitors of influenza virus replication. *Nature*, **1993**, 363, 418-423.

[197] Varghese, J.; Epa, V.; Colman, P. Three-dimensional structure of the complex of 4-guanidino-Neu5Ac2en and influenza virus neuraminidase. *Protein Sci.* **1995**, 4, 1081-1087.

[198] "Merck Manual Online, Breast Cancer", available at http://www.merck.com/mmpe/print/sec18/ch253/ch253e.html.

[199] American Cancer Society. Breast Cancer Facts & Figures **2009**. Atlanta: American Cancer Society, Inc. 1-40.

[200] Keen, J.; Davidson, N. The biology of breast carcinoma. *Cancer*, **2003**, 97, 825-833.

[201] Sunpaweravong, S.; Sunpaweravong, P. Recent developments in critical genes in the molecular biology of breast cancer. *Asian J. Surg.*, **2005**, 28, 71-75.

[202] Hulka, B.; Moorman, P. Breast cancer: Hormones and other risk factors. *Maturitas*, **2008**, 61, 203-213.

[203] Thijssen, J. Local biosynthesis and metabolism of oestrogens in the human breast. *Maturitas*, **2004**, 49, 25-33.

[204] Dickson, R.; Lippman, M. Molecular basis of breast cancer. In Mendelsohn J, Howley PH, Israel MA, Liotta LA, Eds. The molecular basis of cancer. WB Saunders Philadelphia, **1995**; ppPA358–86.

[205] Carmichael, P. Mechanisms of action of antiestrogens: Relevance to clinical benefits and risks. *Cancer Invest.*, **1998**, 16, 604–611.

[206] Lippman, M.; Dickson, R. Growth control of normal and malignant breast epithelium. *Prog. Clin. Biol. Res.*, **1990**, 354, 147-178.

[207] Suzuki, T.; Moriya, T.; Ishida, T.; Kimura, M.; Ohuchi, N.; Sasano, H. *In situ* production of estrogens in human breast carcinoma. *Breast Cancer*, **2002**, 9, 296-302.

[208] Brueggemeier, R. Aromatase inhibitors-mechanisms of steroidal inhibitors. *Breast Cancer Res. Treat.*, **1994**, 30, 31-42.

[209] Jong, P.; Blankestein, M.; Ven, J.; Norteir, J.; Thijssen, J. Importance of local aromatase activity in hormone-dependent breast cancer: A review. *Breast*, **2001**, 10, 91-99.

[210] Ryan, K. Biological Aromatisation of Steroids. *J. Biol. Chem*, **1996**, 234, 268-272.

[211] Ryan, K. Conversion of androstenedione to estrone by placental microsomes. *Biochim Biophys. Acta.*, **1958**, 27, 658-659.

[212] Simpson, E.; Mahendroo, M.; Means, G.; Kilgore, M.; Hinshelwood, M.; Graham-Lorence, S.; Amarneh, B.; Ito, Y.; Fisher, C.; Michael, M. Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. *Endocr. Rev*, **1994**, 15, 342-355.

[213] Akhtar, M.; Lee-Robichaud, P.; Akhtar, M.; Wright, J. The impact of aromatase mechanism on other P450s. *J. Steroid Biochem Mol. Biol.*, **1997**, 61, 127-132.

[214] Simpson, E.; Mahendroo, M.; Means, G.; Kilgore, M.; Corbin, C.; Mendelson, C. Tissue-specific promoters regulate aromatase cytochrome P450 expression. *J. Steroid Biochem Mol. Biol.*, **1993**, 44, 321–330.

[215] Kellis, J.; Vickery, L. Purification and characterization of human placental aromatase cytochrome P-450. *J. Biol. Chem*, **1987**, 262, 4413–4420.

[216] Guengerich, F. Characterization of human microsomal cytochrome P-450 enzymes. *Annu. Rev Pharmacol. Toxicol.*, **1989**, 29, 241-264.

[217] Miyairi, S.; Fishman, J. Novel method of evaluating biological 19-hydroxylation and aromatization of androgens. *Biochem Biophys. Res. Commun.*, **1983**, 117, 392-398.

[218] Miyairi, S.; Fishman, J. Radiometric analysis of oxidative reactions in aromatization by placental microsomes. Presence of differential isotope effects. *J. Biol. Chem*, **1985**, 260, 320-325.

[219] Osawa, Y.; Shibata, K.; Rohrer, D.; Weeks, C.; Duax, W. Reassignment of the absolute configuration of 19-substituted 19-hydroxysteroids and stereomechanism of estrogen biosynthesis. *J. Am Chem Soc.*, **1975**, 97, 4400-4402.

[220] Akhtar, M.; Calder, M.; Corina, D.; Wright, J. Mechanistic studies on C-19 demethylation in oestrogen biosynthesis. *Biochem J.* **1982**, 201, 569-580.

[221] Hackett, J.; Brueggemeier, R.; Hadad, C. The final catalytic step of cytochrome p450 aromatase: A density functional theory study. *J. Am Chem Soc.*, **2005**, 127, 5224-5237.

[222] Ghosh, D.; Griswold, J.; Erman, M.; Pangborn, W. Structural basis for androgen specificity and oestrogen synthesis in human aromatase. *Nature*, **2009**, 457, 219-223.

[223] Labrie, F.; Luu-The, V.; Labrie, C.; Belanger, A.; Simard, J.; Lin, S.; Pelletier, G. Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. *Endocr. Rev*, **2003**, 24, 152-182.

[224] Purohit, A.; Reed, M. Regulation of estrogen synthesis in postmenopausal women. *Steroids*, **2002**, 67, 979-983.

[225] James, V.; McNeill, J.; Lai, L.; Newton, C.; Ghilchik, M.; Reed, M. Aromatase activity in normal breast and breast tumor tissues: *in vivo* and *in vitro* studies. *Steroids*, **1987**, 50, 269-279.

[226] Miller, W.; Mullen, P.; Sourdaine, P.; Watson, C.; Dixon, J.; Telford, J. Regulation of aromatase activity within the breast. *J. Steroid Biochem Mol. Biol.*, **1997**, 61, 193-202.

[227] Reed, M.; Topping, L.; Coldham, N.; Purohit, A.; Ghilchik, M.; James, V. Control of aromatase activity in breast cancer cells: The role of cytokines and growth factors. *J. Steroid Biochem Mol. Biol.*, **1993**, 44, 589-596.

[228] Reed, M. The role of aromatase in breast tumors. *Breast Cancer Res. Treat.*, **1994**, 30, 7-17.

[229] Bulun, S.; Price, T.; Aitken, J.; Mahendroo, M.; Simpson, E. A link between breast cancer and local estrogen biosynthesis suggested by quantification of breast adipose tissue aromatase cytochrome P450 transcripts using competitive polymerase chain reaction after reverse transcription. *J. Clin. Endocrinol. Metab.*, **1993**, 77, 1622-1628.

[230] Means, G.; Kilgore, M.; Mahendroo, M.; Mendelson, C.; Simpson, E. Tissue-specific promoters regulate aromatase cytochrome P450 gene expression in human ovary and fetal tissues. *Mol. Endocrinol.*, **1991**, 5, 2005-2013.

[231] McPhaul, M.; Herbst, M.; Matsumine, H.; Young, M.; Lephart, E. Diverse mechanisms of control of aromatase gene expression. *J Steroid Biochem Mol. Biol.*, **1993**, 44, 341-346.

[232] de Jong, P.; van de Ven, J.; Nortier, H.; Maitimu-Smeele, I.; Donker, T.; Thijssen, J.; Slee, P.; Blankenstein, R. Inhibition of breast cancer tissue aromatase activity and estrogen concentrations by the third-generation aromatase inhibitor vorozole. *Cancer Res.*, **1997**, 57, 2109-2011.

[233] Santen, R.; Santner, S.; Davis, B.; Veldhuis, J.; Samojlik, E.; Ruby, E. Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma. *J. Clin. Endocrinol. Metab.*, **1978**, 47, 1257–1265.

[234] Stuart-Harris, R.; Dowsett, M.; Bozek, T.; McKinna, J. A.; Gazet, J.C.; Jeffcoate, S.L.; Kurkure, A.; Carr, L.; Smith, I. Low-dose aminoglutethimide in treatment of advanced breast cancer. *Lancet*, **1984**, 2, 604–607.

[235] Dutta, U.; Pant, K. Aromatase inhibitors: Past, present and future in breast cancer therapy. *Med. Oncol.*, **2008**, 5, 13-24.

[236] Séralini, G.; Moslemi, S. Aromatase inhibitors: Past, present and future. *Mol. Cell Endocrinol.*, **2001**, 78, 17-31.

[237] Nissen, P.; Hansen, J.; Ban, N.; Moore, P.; Steitz, T. The structural basis of ribosome activity in peptide bond synthesis. *Science*, **2000**, 289, 920-930.

[238] Dasgupta, S.; Murumkar, P.; Giridhar, R.; Yadav, M. Current perspective of TACE inhibitors: A review. *Bioorg. Med. Chem*, **2009**, 17, 444-459.

[239] Wasserman, Z.; Duan, J.; Voss, M.; Xue, C.; Cherney, R.; Nelson, D.; Hardman, K.; Decicco, C. Identification of a selectivity determinant for inhibition of tumor

necrosis factor-alpha converting enzyme by comparative modeling. *Chem. Biol.*, 2003, 10, 215-223.

[240] Duan, J.; Chen, L.; Wasserman, Z.; Lu, Z.; Liu, R.; Covington, M.; Qian, M.; Hardman, K.; Magolda, R.; Newton, R.; Christ, D.; Wexler, R.; Decicco, C. Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structure-activity relationships. *J. Med. Chem*, 2002, 45, 4954-4957.

[241] Niu, X.; Umland, S.; Ingram, R.; Beyer, B. M.; Liu, Y. H.; Sun, J.; Lundell, D.; Orth, P. IK682, a tight binding inhibitor of TACE. *Arch. Biochem. Biophys.*, 2006, 451, 43-50.

[242] Sheppeck, J.; Tebben, A.; Gilmore, J.; Yang, A.; Wasserman, Z.; Decicco, C.; Duan, J. A molecular modeling analysis of novel non-hydroxamate inhibitors of TACE. *Bioorg. Med. Chem. Lett.*, 2007, 17, 1408-1412.

[243] Sheppeck, J.; Gilmore, J.; Tebben, A.; Xue, C.; Liu, R.; Decicco, C.; Duan, J. Hydantoins, triazolones, and imidazolones as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE). *Bioorg. Med. Chem. Lett.*, 2007, 17, 2769-2674.

[244] Lukacova, V.; Zhang, Y.; Kroll, D.; Raha, S.; Comez, D.; Balaz, S., A comparison of the binding sites of matrix metalloproteinases and tumor necrosis factor-alpha converting enzyme: implications for selectivity. *J. Med. Chem*, 2005, 48, 2361-2370.

[245] Zhao, Y.; Feng, W.; Yang, Y.; Ling, L.; Chen, R. Comparison of properties of tumor necrosis factor-alpha converting enzyme (TACE) and some matrix metalloproteases (MMPs) in catalytic domains. *J. Huazhong. Univ. Sci. Technolog. Med. Sci.*, 2006, 26, 637-639.

[246] Bahia, M.; Silakari, O. Generation of Selective TACE Inhibitors: Ligand and Structure Based Molecular Modeling, Virtual Screening, Counter Pharmacophore Screening to Get Selective Molecules. *QSAR Comb. Sci.(Molecular Informatics)*, 2009, 28, 1317-1333.

[247] Bahia, M.; Silakari, O. Strategy for generation of new TACE inhibitors: pharmacophore and counter pharmacophore modeling to remove non-selective hits. *Medicinal Chemistry Research*, 2010, In press.

[248] Bahia, M.; Gade, S.; Mahmood, S.; Muttineni, R.; Silakari, O. Anthranilate derivatives as TACE inhibitors: Docking based CoMFA and CoMSIA analyses. *J. Mol. Model.*, 2010, In press.

[249] Feng, W.; Zhao, Y.; Huang, W.; Yang, Y. Molecular modeling and biological effects of peptidomimetic inhibitors of TACE activity. *J. Enzyme Inhib. Med. Chem.*, 2010, 25, 459-466.

[250]. Yu, W.; Guo, Z.; Orth, P.; Madison, V.; Chen, L.; Dai, C.; Feltz, R.; Girijavallabhan, V.; Kim, S.; Kozlowski, J.; Lavey, B.; Li, D.; Lundell, D.; Niu, X.; Piwinski, J.; Popovici-Muller, J.; Rizvi, R.; Rosner, K.; Shankar, B.; Shih, N.; Siddiqui, M.; Sun, J.; Tong, L.; Umland, S.; Wong, M.; Yang, D.; Zhou, G.

Discovery and SAR of hydantoin TACE inhibitors. *Bioorg. Med. Chem. Lett.*, 2010, 20, 1877-1880.

[251] Le, L.; Lee, E.; Schulten, K.; Truong, T. Molecular modeling of swine influenza A/H1N1, Spanish H1N1, and avian H5N1 flu N1 neuraminidases bound to Tamiflu and Relenza. *PLoS Curr.*, 2009, RRN1015.

[252] Wang, Y.; Chan, C.; Su, Z.; Chen, C. Homology modeling, docking, and molecular dynamics reveal HR1039 as a potent inhibitor of 2009 A(H1N1) influenza neuraminidase. *Biophys. Chem*, 2010, 147, 74-80.

[253] Rungrotmongkol, T.; Intharathep, P.; Malaisree, M.; Nunthaboot, N.; Kaiyawet, N.; Sompornpisut, P.; Payungporn, S.; Poovorawan, Y.; Hannongbua, S. Susceptibility of antiviral drugs against 2009 influenza A (H1N1) virus. *Biochem Biophys. Res. Commun.*, 2009, 385, 390-394.

[254] Rungrotmongkol, T.; Malaisree, M.; Nunthaboot, N.; Sompornpisut, P.; Hannongbua, S. Molecular prediction of oseltamivir efficiency against probable influenza A (H1N1-2009) mutants: molecular modeling approach. *Amino Acids*, 2010, 39, 393-398.

[255] Wang, S.; Du, Q.; Huang, R.; Zhang, D.; Chou, K. Insights from investigating the interaction of oseltamivir (Tamiflu) with neuraminidase of the 2009 H1N1 swine flu virus. *Biochem Biophys. Res. Commun.*, 2009, 386, 432-436.

[256] Durrant, J.; McCammon, J. Potential drug-like inhibitors of Group 1 influenza neuraminidase identified through computer-aided drug design. *Comput. Biol. Chem*, 2010, 34, 97-105.

[257] Grienke, U.; Schmidtke, M.; Kirchmair, J.; Pfarr, K.; Wutzler, P.; Durrwald, R.; Wolber, G.; Liedl, K. R.; Stuppner, H.; Rollinger, J. M. Antiviral potential and molecular insight into neuraminidase inhibiting diarylheptanoids from Alpinia katsumadai. *J. Med. Chem*, 2010, 53, 778-786.

[258] Sun, J.; Cai, S.; Yan, N.; Mei, H. Docking and 3D-QSAR studies of influenza neuraminidase inhibitors using three-dimensional holographic vector of atomic interaction field analysis. *Eur. J. Med. Chem*, 2010, 45, 1008-1014.

[259] Jing, J.; Gui-Zhao; Mei, Hu; Zhang, Qiao-Xia; Li, Zhi-Liang; Lv, Feng-Lin. QSAR studies on influenza neuraminidase inhibitors-acylthiourea analoge. *Chinese Journal of Structural Chemistry*, 2009, 28, 200-204.

[260] Abu Hammad, A.; Taha, M. Pharmacophore modeling, quantitative structure-activity relationship analysis, and shape-complemented *in silico* screening allow access to novel influenza neuraminidase inhibitors. *J. Chem. Inf. Model.*, 2009, 49, 978-996.

[261] Li, Y.; Zhou, B.; Wang, R. Rational design of Tamiflu derivatives targeting at the open conformation of neuraminidase subtype 1. *J. Mol. Graph. Model.*, 2009, 28, 203-219.

[262] D'Souza, C.; Kanyalkar, M.; Joshi, M.; Coutinho, E.; Srivastava, S. Search for novel neuraminidase inhibitors: Design, synthesis and interaction of oseltamivir derivatives with model membrane using docking, NMR and DSC methods. *Biochim Biophys. Acta*, 2009, 1788, 1740-1751.

[263] De Groot, M.; Ekins, S. Pharmacophore modeling of cytochromes P450. *Adv Drug Deliv Rev*, 2002, 54, 367-383.

[264] Karkola, S.; Höltje, H.; Wähälä, K. A three-dimensional model of CYP19 aromatase for structure-based drug design. *J. Steroid Biochem Mol. Biol.*, 2007, 105, 63-70.

[265] Loge, C.; Le Borgne, M.; Marchand, P.; Robert, J.-M.; Le Baut, G.; Palzer, M.; Hartmann, R. W. Three-dimensional model of cytochrome P450 human aromatase. *J. Enzym Inhib. Med. Chem, 2005*, 20, 581-585.

[266] Murthy, J.; Nagaraju, M.; Sastry, G.; Rao, A.; Sastry, G. Active site acidic residues and structural analysis of modelled human aromatase: A potential drug target for breast cancer. *J. Comput-Aided Mol. Des.*, 2005, 19, 857-870.

[267] Schuster, D.; Laggner, C.; Steindl, T.; Palusczak, A.; Hartmann, R.; Langer, T. Pharmacophore modeling and *in silico* screening for new P450 19 (aromatase) inhibitors. *J. Chem Inf. Model.*, 2006, 46, 1301-1311.

[268] Nagar, S.; Islam, M.; Das, S.; Mukherjee, A.; Saha, A. Pharmacophore mapping of flavone derivatives for aromatase inhibition. *Mol. Divers.*, 2008, 12, 65-76.

[269] Nagar, S.; Saha, A. QSAR modeling and pharmacophore mapping of isoflavone derivatives for aromatase inhibitory activity. *Int. J. Pharm Pharmaceutical Sci.*, 2010, 2, 126-131.

[270] Nagar, S.; Islam, M.; Das, S.; Mukherjee, A.; Saha, A. Pharmacophore searching of benzofuran derivatives for selective CYP19 aromatase inhibition. *Lett. Drug Des. Discov*, 2009, 6, 38-45.

[271] Nagar, S.; Saha, A. Modeling of diarylalkyl-imidazole and diarylalkyl-triazole derivatives as potent aromatase inhibitors for treatment of hormone-dependent cancer. *J. Comput. Chem.*, 2010, 31, 2342-2353.

[272] Nagar, S.; Saha, A. Exploring benzcyclo derivatives as potent aromatase inhibitors using ligand-based modeling studies. *Eur. J. Med. Chem.*, 2010, 45, 4307-4315.

[273] Muftuoglu, Y.; Mustata, G. Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). *Bioorg. Med. Chem Lett.*, 2010, 20, 3050-3064.

[274] Neves, M.; Dinis, T.; Colombo, G.; Sáe Melo, M. An efficient steroid pharmacophore-based strategy to identify new aromatase inhibitors. *Eur. J. Med. Chem*, 2009, 44, 4121-4127.

[275] Oliveira, A.; Ramalho, T.; D Cunha, E. QSAR study of androstenedione analogs as aromatase inhibitors. *Lett. Drug Des. Discov*, 2009, 6, 554-562.

[276] Jackson, T.; Woo, L.; Trusselle, M.; Chander, S.; Purohit, A.; Reed, M.; Potter, B. Dual aromatase-sulfatase inhibitors based on the anastrozole template: Synthesis,

in vitro SAR, molecular modeling and *in vivo* activity. *Org. Biomol. Chem*, 2007, 5, 2940-2952.

[277] Leonetti, F.; Favia, A.; Rao, A.; Aliano, R.; Paluszcak, A.; Hartmann, R.W.; Carotti, A. Design, synthesis, and 3D QSAR of novel potent and selective aromatase inhibitors. *J. Med. Chem*, 2004, 47, 6792-6803.

[278] Beger, R.; Buzatu, D.; Wilkes, J.; Lay Jr., J. ^{13}C NMR Quantitative Spectrometric Data-Activity Relationship (QSDAR) Models of Steroids Binding the Aromatase Enzyme. *J. Chem. Inform. Comp. Sci.*, 2001, 41, 1360-1366.

[279] Numazawa, M.; Shelangouski, M.; Nagasaka, M. Probing the binding pocket of the active site of aromatase with 6-ether or 6-ester substituted androst-4-ene-3,17-diones and their diene and triene analogs. *Steroids*, 2000, 65, 871-882.

[280] Cavalli, A.; Greco, G.; Novellino, E.; Recanatini, M. Linking CoMFA and protein homology models of enzyme-inhibitor interactions: An application to non-steroidal aromatase inhibitors. *Bioorg. Med. Chem*, 2000, 8, 2771-2780.

[281] Kao, Y.-C.; Zhou, C.; Sherman, M.; Laughton, C.A.; Chen, S. Molecular basis of the inhibition of human aromatase (estrogen synthetase) by flavone and isoflavone phytoestrogens: A site-directed mutagenesis study. *Environ. Health Perspect.*, 1998,106, 85-92.

[282] Numazawa, M.; Oshibe, M.; Yamaguchi, S.; Tachibana, M. Time-dependent inactivation of aromatase by 6-alkylandrosta-1,4-diene-3,17-diones. Effects of length and configuration of the 6-alkyl group. *J. Med. Chem*, 1996, 39, 1033-1038.

[283] Numazawa, M., Kamiyama, T., Tachibana, M., Oshibe, M. Synthesis and structure-activity relationships of 6-substituted androst-4-ene analogs as aromatase inhibitors. *J. Med. Chem*, 1996, 39, 2245-2252.

[284] Furet, P.; Batzl, C.; Bhatnagar, A.; Francotte, E.; Rihs, G.; Lang, M. Aromatase inhibitors: Synthesis, biological activity, and binding mode of azole-type compounds. *J. Med. Chem*, 1993, 36, 1393-1400.

[285] Cepa, M.; Correia-Da-Silva, G.; Tavares Da Silva, E.; Roleira, F.; Hong, Y.; Chen, S.; Teixeira, N. Molecular mechanisms of aromatase inhibition by new A, D-ring modified steroids. *Biol. Chem*, 2008, 389, 1183-1191.

[286] Laughton, C.; Neidle, S. Inhibitors of the P450 enzymes aromatase and lyase. Crystallographic and molecular modeling studies suggest structural features of pyridylacetic acid derivatives responsible for differences in enzyme inhibitory activity. *J. Med. Chem*, 1990, 33, 3055-3060.

[287] Ghosh, D; Griswold, J; Erman, M; Pangborn, W. X-ray structure of human aromatase reveals an androgen-specific active site, *J. Steroid Biochem Mol. Biol.*, 2010, 118, 197-202.

[288] Cherney, R.; Duan, J.; Voss, M.; Chen, L.; Wang, L.; Meyer, D.; Wasserman, Z. *et al.* Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-a converting enzyme inhibitors. *J. Med. Chem*, 2003, 46, 1811–1823.

[289] Eisenstein, E.; Hensley, P. Ligand binding-promoted conformational changes in yeast ornithine transcarbamoylase. *J. Bio. Chem*, **1986**, 261, 6192–6200.

[290] Cho, S.; Tropsha, A. Cross-validated R^2-guided region selection for comparative molecular field analysis: a simple method to achieve consistent results. *J. Med. Chem.*, **1995**, 38, 1060–1066.

[291] Gilmore, J.; King, B.; Harris, C.; Maduskuie, T.; Mercer, S.; Liu, R.; Covington, M.; Qian, M.; Ribadeneria, M.; Vaddi, K.; Trzaskos, J.; Newton, R.; Decicco, C.; Duan, J. Synthesis and structure–activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors. *Bioorg. Med. Chem. Lett.*, **2006**, 16, 2699–2704.

[292] Chen, X.; Ghavimi, B.; Corbett, R.; Xue, C.; Liu, R.; Covington, M.; Qian, M.; Vaddi, K.; Christ, D.; Hardman K.; Ribadeneria, M.; Trzaskos J.; Newton, R.; Decocco, C.; Duan, J. A new 4-(2-methylquinolin-4-ylmethyl)phenyl P1' group for the beta-amino hydroxamic acid derived TACE inhibitors. *Bioorg. Med. Chem Lett*, **2007**, 17, 1865–1870.

[293] Duan, J.; Lu, Z.; Xue, C.; He, X.; Seng, J.; Roderick, J.; Wasserman, Z.; Liu, R.; Covington, M.; Magolda, R.; Newton, R.; Trzaskos, J.; Decicco, C. Discovery of N-hydroxy-2-(2-oxo-3-pyrrolidinyl)acetamides as potent and selective inhibitors of tumor necrosis factor-α converting enzyme (TACE). *Bioorg. Med. Chem Lett.*, **2003**, 13, 2035-2040.

[294] Xue, C.; He, X.; Roderick, J.; Corbett, R.; Duan, J.; Liu, R.; Covinton, M.; Qian, M.; Ribadeneira, M.; Vaddi, K.; Christ, D.; Newton, R.; Trzaskos, J.; Magolda, R.; Wexler, R.; Decicco, C. Rational design, synthesis and structure–activity relationships of a cyclic succinate series of TNF-α converting enzyme inhibitors. Part 2: lead optimization. *Bioorg. Med. Chem Lett.*, **2003**, 13, 4299-4304.

[295] Gilmore, J.; Bryan, W. King.; Asakawa, N.; Harrison, K.; Tebben, A.; Sheppeck, II J.; Liu, R.; Covington, M.; Duan, J. Synthesis and structure–activity relationship of a novel, non-hydroxamate series of TNF-α converting enzyme inhibitors. *Bioorg. Med. Chem Lett.*, **2007**, 17, 4678-4682.

[296] Duan, J.; Lu, Z.; Wasserman, Z.; Liu, R.; Convington, M.; Decicco, C. Non-hydroxamate 5-phenylpyrimidine-2,4,6-trione derivatives as selective inhibitors of tumor necrosis factor-α converting enzyme. *Bioorg. Med. Chem Lett.*, **2005**, 15, 2970-2973.

[297] Sheppeck, J.; Gilmore, J.; Yang, A.; Chen, X.; Xue, C.; Roderick, J.; Liu, R.; Covington, M.; Decicco, C.; Duan, J. Discovery of novel hydantoins as selective non-hydroxamate inhibitors of tumor necrosis factor-α converting enzyme (TACE). *Bioorg. Med. Chem Lett.*, **2007**, 17, 1413-1417.

[298] Ott, G.; Asakawa, N.; Lu, Z.; Liu, R.; Convington, M.; Vaddi, K.; Quin, M.; Newton, R.; Christ, D.; Traskos, J.; Decicco, C.; Duan, J. α,β-Cyclicbenzamido hydroxamic acids: Novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-a converting enzyme (TACE). *Bioorg. Med. Chem Lett.*, **2008**, 18, 694–699.

[299] Ott, G.; Asakawa, N.; Liu, R.; Convington, M.; Vaddi, K.; Newton, R.; Traskos, J.; Christ, D.; Galya, L.; Cholz, T.; Marshall, W.; Duan, J. α,β-Cyclic-b-benzamido hydroxamic acids: Novel oxaspiro[4.4]nonane templates for the discovery of potent, selective, orally bioavailable inhibitors of tumor necrosis factor-alfa converting enzyme (TACE). *Bioorg Med Chem Lett.*, 2008, 18, 1288–1292.

[300] Lu, Z.; Ott, G.; Anad, R.; Liu, R.; Convington, M.; Vaddi, K.; Qian, M.; Newton, R.; Christ, D.; Traskos, J.; Duan, J. Potent, selective, orally bioavailable inhibitors of tumor necrosis factor-a converting enzyme (TACE): Discovery of indole, benzofuran, imidazopyridine and pyrazolopyridine P1' substituents. *Bioorg. Med. Chem Lett.*, 2008, 18, 1958–1962.

[301] Ott, G.; Asakawa, N.; Lu, Z.; Anad, R.; Liu, R.; Convington, M.; Vaddi, K.; Qian, M.; Newton, R.; Christ, D.; Traskos, J.; Duan, J. Potent, exceptionally selective, orally bioavailable inhibitors of TNF-a converting enzyme (TACE): Novel 2-substituted-1*H*-benzo[d]imidazol-1-yl)methyl)benzamide P1'substituents. *Bioorg. Med. Chem Lett.*, 2008, 18, 1577–1582.

[302] BLAST-2 Search: http://www.expasy.org/blast

[303] Entry A7Y1V1: http://www.expasy.org/uniport/A7Y1V1

[304] Grootveld, M.; McDermott, M. BMS-561392. *Curr. Opin. Investig. Drugs*, 2003, *4*, 598-602.

[305] Cherney, R.; King, B.; Gilmore, J.; Liu, R.; Covington, M.; Duan, J.; Decicco, C.P. Conversion of potent MMP inhibitors into selective TACE inhibitors. *Bioorg. Med. Chem Lett.*, 2006, 16, 1028-1031.

[306] Cherney, R.; Mo, R.; Meyer, D.; Hardman, K.; Liu, R.; Covington, M.; Qian, M.; Wasserman, Z.; Christ, D.; Trzaskos, J.; Newton, R.; Deccico, C. Sultam hydroxamates as matrix metalloproteinase inhibitors. *J. Med. Chem*, 2004, 47, 2981-2990.

[307] Govind, R., B.; Bandarage, U.; Wang, T.; Come, J.; Perola, E.; Wei, Y.; Tian, S.; Saunders, J. Novel thiol based TACE inhibitors: Rational design, synthesis, and SAR of thiol-containing aryl sulphonamides. *Bioorg. Med. Chem Lett.*, 2007, 17, 2250-2053.

[308] Bandarage, U.; Wang, T.; Come, J.; Perola, E.; Wei, Y.; Govind Rao, B. Novel thiol based TACE inhibitors. Part 2: Rational design, synthesis, and SAR of thiol containing aryl sulphons. *Bioorg. Med. Chem Lett.*, 2008, 18, 44-48.

[309] Thabet, M.; Huizinga, T. Drug evaluation: apratastat, a novel TACE/MMP inhibitor for rheumatoid arthritis. *Curr. Opin. Invest. Drugs*, 2006, 7, 1014-1019.

[310] Duan, J.; Chen, L.; Lu, Z.; Xue, C-B.; Liu, R-Q.; Covington, M.; Qian, M.; Wasserman, Z.; Vaddi, K.; Christ, D.; Trzaskos, J.; Newton, R.; Decicco, C. Discovery of beta-benzamido hydroxamic acids as potent, selective, and orally bioavailable TACE inhibitors. *Bioorg. Med. Chem Lett.*, 2008, 18, 241-246.

[311] SYBYL 7.0, Tripos, Inc., 1699 South Hanley Road, St. Louis, Missouri 63144, USA.3.

[312] Clark, M.; Crammer, R.; van Opdenbosh, N. *J.* Validation of the general purpose Tripos 5.2 forcefield. *Comput. Chem* **1989**, 10, 982-1012.

[313] Wang, G.; Chen, Y.; Wang, S.; Gentles, R.; Sowin, T.; Kati, W.; Muchmore, S.; Giranda, V.; Stewart, K.; Sham, H.; Kempf, D.; Laver, W. Design, synthesis, and structural analysis of influenza neuraminidase inhibitors containing pyrrolidine cores. *J. Med. Chem,* **2001**, 44, 1192-1201.

[314] Chand, P.; Kotian, P.; Dehghani, A.; El-Kattan, Y.; Lin, T.; Hutchison, T.; Babu, Y.; Bantia, S.; Elliott, A.; Montgomery, J. Systematic structure-based design and stereoselective synthesis of novel multisubstituted cyclopentane derivatives with potent antiinfluenza activity. *J. Med. Chem,* **2001**, 44, 4379-4392.

[315] Kim, C.; Lew, W.; Williams, M.; Wu, H.; Zhang, L.; Chen, X.; Escarpe, P.; Mendel, D.; Laver, W.; Stevens, R. Structure-activity relationship studies of novel carbocyclic influenza neuraminidase inhibitors. *J. Med. Chem,* **1998**, 41, 2451-2460.

[316] Brueggemeier, R.; Hackett, J.; Diaz-Cruz, E. Aromatase inhibitors in the treatment of breast cancer. *Endocr. Rev,* **2005**, 26, 331–345.

[317] Johannessen, D.; Engan, T.; Di Salle, E.; Zurlo, M.; Paolini, J.; Ornati, G.; Piscitelli, G.; Kvinnsland, S.; Lonning, P. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: A phase I study. *Clin. Cancer Res.,* **1997**, 3, 1101-1108.

[318] Lonning, P. Exemestane: A review of its clinical efficacy and safety. *The Breast,* **2001**, 10, 98-208.

[319] Choueiri, T.; Alemany, C.; Abou-Jawde, R.; Budd, G. Role of aromatase inhibitors in the treatment of breast cancer. *Clin. Ther.*, **2004**, 26, 1199-1214.

[320] Takahashi, M.; Yamashita, K.; Numazawa, M. Probing the binding pocket of the active site of aromatase with 2-phenylaliphatic androsta-1,4-diene-3,17-dione steroids. *Steroids,* **2010**, 75, 330-337.

[321] Thompson, E.; Siiteri, P. Utilization of oxygen and reduced nicotinamide adenine dinucleotide phosphate by human placental microsomes during aromatization of androstenedione. *J. Biol. Chem,* **1974**, 249, 5364-5372.

[322] ACD/CHEMSKETCH FREEWARE, version 10.00, Toronto, ON, Canada: Advanced Chemistry development Inc.

[323] Protein data bank: www.rcsb.org

[324] Dewar, M.; Zoebisch, E.; Healy, E.; Stewart, J. Development and use of quantum mechanical molecular models. 76. AM1: A new general purpose quantum mechanical molecular model. *J. Am Chem Soc.*, 107, **1985**, 3902-3909.

[325] Clark, M.; Cramer, R.; Jones, D.; Patterson, D.; Simeroth, P. Comparative molecular field analysis (CoMFA). 2. Toward its use with 3D-structural databases. *Tetrahedron Comput. Methodol.*, **1990**, 3, 47–59.

[326] http://zinc.docking.org/vendor0/asin/index.html asin_p0.0. sdf database version 2006.3, # in catalog: 372187, made up of 45,533 molecules.

****